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Strengths and limitations of this study
 ► The first study to systematically assess visually guid-
ed reaching in patients with cognitive impairment.
 ► Includes a simple tablet- based task (lateral reaching) 
that could be readily translated to clinical settings to 
assess the presence of peripheral misreaching.
 ► Case–control statistical tests of deficit are inherently 
low powered, so subtle deficits of reaching may not 
be detected at the level of individual patients.
AbStrACt
Introduction Recent evidence has implicated the 
precuneus of the medial parietal lobe as one of the first 
brain areas to show pathological changes in Alzheimer’s 
disease (AD). Damage to the precuneus through focal 
brain injury is associated with impaired visually guided 
reaching, particularly for objects in peripheral vision. This 
raises the hypothesis that peripheral misreaching may be 
detectable in patients with prodromal AD. The aim of this 
study is to assess the frequency and severity of peripheral 
misreaching in patients with mild cognitive impairment 
(MCI) and AD.
Methods and analysis Patients presenting with amnestic 
MCI, mild- to- moderate AD and healthy older- adult 
controls will be tested (target N=24 per group). Peripheral 
misreaching will be assessed using two set- ups: a 
tablet- based task of lateral reaching and motion- tracked 
radial reaching (in depth). There are two versions of each 
task, one where participants can look directly at targets 
(free reaching), another wheren they must maintain 
central fixation (peripheral reaching). All tasks will be 
conducted first on their dominant, and then their non- 
dominant side. For each combination of task and side, 
a Peripheral Misreaching Index (PMI) will be calculated 
as the increase in absolute reaching error between free 
and peripheral reaching. Each patient will be classified as 
showing peripheral misreaching if their PMI is significantly 
abnormal, by comparison to control performance, on either 
side of space. We will then test whether the frequency 
of peripheral misreaching exceeds the chance level in 
each patient group and compare the overall severity of 
misreaching between groups.
Ethics and dissemination Ethical approval was provided 
by the National Health Service (NHS) East of England, 
Cambridge Central Research Ethics Committee (REC 19/
EE/0170). The results of this study will be published 
in a peer- reviewed journal and presented at academic 
conferences.
IntroduCtIon
The pathophysiological cascade that leads 
to Alzheimer’s disease (AD) can begin up 
to 20 years before the onset of cognitive 
problems in both autosomal and sporadic 
AD.1–5 In dominant and early- onset cases, 
there is evidence that the precuneus is one 
of the earliest regions to be affected.5 6 Focal 
damage in and around this brain area is 
known to be associated with deficits of visu-
ally guided action.7 One example of such a 
condition is optic ataxia, an impairment of 
misreaching typically reflected in peripheral 
vision.8 9 Patients with optic ataxia do not 
often report this symptom and it is rarely 
assessed in clinical settings, and it can there-
fore go undetected.10 The changes observed 
in the precuneus in prodromal AD, and 
the link between the precuneus and optic 
ataxia, raise the hypothesis that optic ataxic 
misreaching may be detectable in patients 
with prodromal AD.
 Specific hypothesis
The hypothesis that peripheral misreaching 
is a feature of AD means that individual 
patients with AD, and possibly those with mild 
cognitive impairment (MCI), may show an 
abnormally large inflation of reaching errors 
when aiming for targets in peripheral vision, 
as compared with targets in free vision. At a 
group level, patients with AD and, to a lesser 
extent, patients with MCI may show signifi-
cantly greater peripheral misreaching than 
healthy controls (HCs).
MEthodS
Study setting
The study is a collaboration between clini-
cians and University staff at the University of 
 o
n
 June 10, 2020 at University of Edinburgh. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035021 on 4 June 2020. Downloaded from 
2 Mitchell AG, et al. BMJ Open 2020;10:e035021. doi:10.1136/bmjopen-2019-035021
Open access 
Edinburgh (UoE) and University of East Anglia (UEA). 
The details of recruitment and site information can be 
found in the online supplementary materials. Data collec-
tion for this study began on 03 October 2019 and 8 of 48 
patients have taken part. Data for HCs have already been 
collected.
Participants
Patients with a diagnosis of amnestic MCI or typical 
(amnestic) mild- to- moderate AD will be invited to take 
part. To ensure mild- to- moderate cases of AD, patients 
will have a score >50 in the most recent administration 
of Addenbrooke’s Cognitive Examination (ACE- III).11 If 
there is no recorded ACE- III score, clinical opinion of 
patient’s condition will be used to assess eligibility.
Older adults without any known neurological disorders 
will be tested as an HC group. To achieve our target of 24 
full datasets per group (Power considerations section), we 
plan to test up to 30 participants in each group, allowing 
for possible withdrawals.
Inclusion criteria
For all participant groups, the ability to give informed 
consent is the initial inclusion criterion. Additional inclu-
sion criteria are then applied to each group.
Control group inclusion criteria:
 ► Aged 50–75. (NB. The age- range for controls is 
targeted at the expected age range for patients, but the 
allowable range of ages for patients is wider than this, 
in order not to restrict recruitment unnecessarily.)
 ► No reported neurological or neurodegenerative 
conditions.
MCI group inclusion criteria:
 ► Aged 45–85.
 ► Clinical diagnosis of MCI with an amnestic pattern 
of presentation. This includes an observed deficit 
on cognitive/neuropsychological testing suggesting 
amnestic and visuospatial profile deficit, low β-amy-
loid, elevated phosphorylated Tau, regional atrophy 
on magnetic resonance brain imaging and/or 
regional perfusion changes on HMPAO- SPECT 
(Single photon emission computed tomography with 
hexamethyl propylenamine oxime).
AD group inclusion criteria:
 ► Aged 45–85.
 ► Clinical diagnosis of AD.
Exclusion criteria
For all participant groups, the following exclusion criteria 
are applied:
 ► Significant difficulty communicating or under-
standing instructions in English.
 ► Significant, uncorrected visual impairment (eg, cata-
ract, macular degeneration, scotoma, amblyopia and 
strabismus).
 ► Conditions that could interfere with smooth hand 
movements (eg, ataxia, essential tremor and severe 
arthritis).
 ► Clinical features suggestive of Lewy body pathology 
(eg, visual hallucinations or rapid eye- movement 
(REM) sleep disorder).
Public and patient involvement
Patients with MCI or AD and their carers were involved 
in the early stages of planning and development. A focus 
group was held at the Anne Rowling Clinic in Edinburgh 
where patients and carers had the opportunity to try out 
prototypes of the tablet- based reaching task and provide 
feedback on task design. This feedback was used to opti-
mise the final task for patient accessibility and clarity.
tasks
Two different set- ups will be used to assess peripheral 
reaching: a tablet- based assessment of reaching in the 
frontoparallel plane (lateral reaching), and a motion- 
tracking assessment of reaching in radial depth (radial 
reaching). Participants will complete two versions of each 
reaching task: a version in which participants look directly 
at targets before reaching to them (free reaching); and a 
version where central fixation is maintained (peripheral 
reaching). Any general factors affecting motor accuracy 
should influence both free and peripheral reaching, so 
we will treat the free reaching condition as a baseline 
condition, to be subtracted from peripheral reaching 
performance, to isolate the specific increase in error due 
to peripheral target presentation.12 The critical outcome 
measure is therefore the inflation of absolute reaching 
error in peripheral reaching relative to free reaching.
Before testing, the participant’s dominant writing hand 
is identified (by self- report). All tasks are completed first 
on the dominant side, using the dominant hand, followed 
by the non- dominant side and hand. Lateral reaching is 
completed first, followed by radial reaching. All tasks are 
performed in the same order for all participants.
Lateral reaching tasks
Stimuli and apparatus
Stimuli are presented on an HP Pavillion ×360 
touch screen (active display 310×175 mm, resolution 
1920×1080 pixels). Tasks are controlled by a custom 
programme written in OpenSesame V.3.2.8 Kafkesque 
Koffka.13 Participants are seated 40 cm away from the 
screen which is positioned with either the right edge 
(left- sided reaching, figure 1A) or the left edge (right- 
sided reaching, figure 1B) of the screen aligned to their 
midline figure 1A figure 1B. A start box (white rectangle, 
2°×2°, 13.96×13.96 mm) is drawn at the edge (right or 
left) of the screen, aligned to participant’s midpoint. 
In some tasks (detailed below) a white fixation cross is 
present (1°×1°, 6.98×6.98 mm), located 34.9 mm (5°) 
directly above the start box. Targets are white circles 
(diameter=2°, 13.96 mm) presented along radial spokes 
at 28°, 33° and 38° to the left (figure 1A) or right 
(figure 1B) of fixation. The experimenter sits across the 
table and monitors eye movements directly.
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Figure 1 Nine target positions for the lateral reaching task 
for left (A) and right (B) hand sides. At a viewing distance of 
40 cm targets are presented at approximately 28°, 33° and 
38° of eccentricity.
 Free reaching
For the first block in the lateral reaching task participants 
are not required to fixate, therefore, the fixation cross is 
absent.
Participants initiate a trial by pressing and holding 
down the start box, which disappears at touch. At this 
point, they may search the screen for a target. After a 
short delay (250–750 ms, randomised 100 ms intervals), a 
target appears at one of nine possible locations. As soon 
as the target appears, participants look at it and make 
one smooth reach to try to touch the target. The target 
remains on the screen until a touch is recorded at any 
location, and then the target disappears and a short beep 
(100 ms, 440 Hz) is played. The validity of the trial is then 
coded by the experimenter using a keyboard; ‘y’—valid 
trial, ‘e’—the participant did not move their eyes to the 
target, ‘v’—void trial, and the start box reappears to begin 
another trial.
If an ‘e’ or ‘v’ is pressed, the corresponding trial is 
repeated until a valid trial is recorded. The block ends 
after a minimum of 27 valid trials (3 per target location), 
or after 50 valid and ‘no eye- movement’ trials.
 Visual detection
This is a simple check to confirm that the participant 
is capable of detecting the targets when presented in 
peripheral vision, to be allowed for a meaningful test of 
peripheral reaching (Peripheral reaching section).
Throughout each trial the participant must gaze at 
the fixation cross. They initiate the trial by pressing and 
holding down the start box, which disappears when 
touched. In order to aid the maintenance of fixation, the 
fixation cross cycles between white and red at the screen 
refresh rate (60 Hz). After a short delay (250–750 ms), a 
target can appear at one of the nine locations for 1 s, or no 
target appears. This is followed by a short beep (100 ms, 
440 Hz) to indicate the end of the trial. The participant 
must verbally report whether or not a target was seen in 
that interval. The experimenter records the response 
using the keyboard (‘y’—yes, ‘n’—no, ‘v’ - void). If the 
participant makes an eye movement, the experimenter 
presses ‘e’ and the trial is repeated. The block ends after 
15 valid (no eye- movement) trials, one for each of the 
nine target locations, and six catch trials with no target.
To progress to the peripheral reaching task, partic-
ipants are required to detect at least 6/9 targets and 
correctly rejects at least 3/6 catch trials. Otherwise, 
testing is discontinued on that side of space.
Peripheral reaching
For peripheral reaching, participants are required to 
gaze at the fixation cross throughout each trial. A trial 
begins by pressing and holding down the start box. When 
touched, the start box disappears and the fixation cross 
cycles between white and red (at a rate of 60 Hz) until 
the trial ends. After a short delay (250–750 ms) a target 
appears at one of nine locations. While maintaining 
fixation, participants make one smooth reaching move-
ment to try to touch the target. The target remains on 
the screen until a touch is recorded at any location, and 
a short beep is played once the target disappears. The 
experimenter then records the validity of the trial; ‘y’—
valid, ‘e’—participant moved their eyes away from fixa-
tion, ‘v’—void trial.
Invalid (‘e’ or ‘v’) trials are repeated until a valid trial 
is recorded. The block ends after a minimum of 27 valid 
trials (three per target location), or after 50 valid and 
‘eye- movement’ trials.
 Radial reaching tasks
Stimulus and Apparatus
An infrared motion- tracking camera (Optotrak Certus, 
Northern Digital) is used to track the reaching movement. 
Infrared- emitting diodes (IREDs) are taped to the tip of 
the right and left index fingers of each participant to track 
the reach in each hand. The Optotrak samples the IRED’s 
3D position at 100 Hz throughout each 2000 ms trial. The 
task is controlled by custom software written in LabView 
(National Instruments) programming environment. The 
stimuli and apparatus reported here are specific to UoE. 
At the second site, UEA, motion tracking was performed 
by using a Qualisys system (Gothenburg, Sweden) and a 
slightly different set up was used. 14
Participants are seated with their head placed in a 
chin- rest in line with the middle of the display. Stimuli 
are back- projected via a mirror onto a screen (1000 mm 
wide × 750 mm deep) that lies flat in- front of the partic-
ipant. A webcam is placed on the screen 50 cm directly 
in- front of the participant, as a fixation point. The live 
 o
n
 June 10, 2020 at University of Edinburgh. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035021 on 4 June 2020. Downloaded from 
4 Mitchell AG, et al. BMJ Open 2020;10:e035021. doi:10.1136/bmjopen-2019-035021
Open access 
Figure 2 Target positions for the radial reaching task 
shown here on both the right- hand and left- hand sides, at 
11.4°, 22.6°, 33.4° and 43.6° from fixation. The start button 
is positioned at the bottom of the screen 40 cm away from 
central fixation. A webcam is placed at the point of central 
fixation (midpoint).
webcam image feeds into a separate laptop, allowing the 
experimenter to monitor gaze. A start button is aligned to 
the centre of the screen, positioned 10 cm in- front of the 
participant, 40 cm away from fixation (figure 2). Targets 
are white circles (diameter=1.60°, 13.96 mm) presented 
at four eccentric locations (11.4°, 22.6°, 33.4° and 43.6° 
away from centre) on each side (figure 2).
Calibration
A calibration procedure is carried out before the reaching 
tasks to record the IRED position at the actual target loca-
tion. A target is displayed at one target location and the 
participant is instructed to cover it completely with their 
reaching finger. Once the target is covered, the experi-
menter presses the start button and the finger location 
is recorded for 2000 ms. A beep plays after 2000 ms, indi-
cating that the participant can move their hand away 
from the target position. Another target appears at the 
next location and the same procedure is repeated. Cali-
bration is run using the ipsilateral hand for four targets 
on the left side and four on the right.
Free reaching
Participants initiate a trial by pressing and holding down 
the start button. As soon as they push the button down, 
participants may look around the screen for a target. 
After 250–750 ms a target appears, participants then look 
directly at the target and reach to touch the target in one 
smooth movement. Optotrak recording is initiated simul-
taneously with target appearance, and the target disap-
pearance is simultaneous with the end of the recording 
after 2000 ms. When the target disappears a short beep 
(100 ms, 440 Hz) plays, the participant leaves their finger 
at its landing position until they hear the beep. After 
the trial, the experimenter codes the trial validity with 
a key- press; ‘Return’—valid, ‘F1’—no eye- movement, 
‘Esc’—void trial. If an invalid trial (‘F1’ or ‘Esc’) is coded 
the trial gets recycled to the end of the block.
The block ends once 28 valid trials (7 per target 
location) are recorded, or after 50 valid and ‘no eye- 
movement’ trials.
 Peripheral reaching
To assess reaching accuracy in the periphery participants 
are required to look directly at central fixation (the 
webcam) throughout each trial. Participants initiate a 
trial by pressing and holding down the start button. After 
250–750 ms a target appears. While maintaining gaze 
on the webcam participants make one smooth reaching 
movement to try to touch the target. After the reach, 
participants leave their finger at its landing position 
until a short beep (100 ms, 440 Hz). The target remains 
on screen for 2000 ms after the trial begins. The motion- 
tracker records the reach throughout the 2000 ms trial. At 
the end of the trial, the experimenter codes trial validity; 
‘Return’—valid trial, ‘F1’—eye movement during trial, 
‘Esc’—void trial. If an invalid trial (‘F1, ‘Esc’) is recorded 
then the trial is recycled to the end of the block.
The block ends after 28 valid trials (7 per target loca-
tion) are recorded, or after 50 valid and ‘eye- movement’ 
trials.
AnAlySIS PlAn
 lateral reaching task
For the critical analyses, a single measure of reaching 
accuracy is taken for each participant, for each combi-
nation of viewing condition (free, peripheral) and side 
(non- dominant, dominant). For each response, the abso-
lute error (in mm, x- axis and y- axis) is recorded as the 
distance of the reach endpoint from the target midpoint. 
The median absolute error is then calculated for each 
target eccentricity, across responses to the three targets 
at that eccentricity, for each combination of viewing 
condition and side. The average absolute error is then 
calculated as the mean of the medians for the three eccen-
tricities, to give the single measure of reaching accuracy 
for each viewing condition at each side.
For the comparison of individual patients against 
control performance, the data are further compressed 
to a single index of performance per side, by subtracting 
reaching accuracy in the free vision condition from that 
in the peripheral condition. We call this value the Periph-
eral Misreaching Index (PMI).
Analysis of single-case deficits
We will screen the control group for outliers that might 
suggest abnormalities, as such values would reduce the 
(already low, see figure 3) power to detect single- case 
deficits. We will use a robust method of outlier detec-
tion based on the median absolute deviation (MAD). 
The MAD can be multiplied by the consistency constant 
1.4826 to estimate the SD, assuming a normal distribu-
tion. Each control participant’s PMI can be expressed as 
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Figure 3 Relation between(A) control sample size and 
power to detect a single- case deficit in a one- tailed test, for 
different sizes of deficit (D, expressed as SD of control mean). 
(B) D and power to detect a deficit, given a control sample 
size of 24, for adjusted (.025) and unadjusted (.05) alpha 
criteria.
a modified Z- score (Z′) by subtracting the group median, 
divided by the MAD *1.4826. If Z′ exceeds 2.5 on either 
side, that participant will be excluded, and replaced. Our 
simulations suggest that, for a group size of 24, we would 
expect to exclude (on average)<1 participant (~0.67) by 
this criterion.
We will next assess, for each side, whether the PMI of 
controls is related to age or sex, by computing Pearson’s 
correlations. If the correlation is ≥0.3 on either side, then 
that variable will be included as a covariate in the subse-
quent case–control comparisons for both sides.
Case–control comparisons will then be run to compare 
each patient’s PMI against control performance on each 
side of space. These comparisons will be based on Craw-
ford and Howell's15 modified t- test; or, if covariates are 
included, we will use the Bayesian Test of Deficit with 
covariates.16 The individual tests will be one- tailed, with an 
alpha level set to 0.025, in order to constrain per- patient 
alpha level (across the two sides) to 0.05. If a patient shows 
a deficit on either side that meets the adjusted criterion 
(0.025), they will be classified as showing periperheral 
misreaching. If a patient shows a deficit on either side 
that would meet the unadjusted criterion (0.05), but not 
the adjusted criterion, they will be classified as showing 
borderline peripheral misreaching.
Finally, a binomial test will test whether the rate of 
observed peripheral misreaching exceeds the rate 
expected by chance (ie, the per- patient adjusted alpha 
level of 0.05). A significant outcome (p<0.05) for either 
patient group will indicate that peripheral misreaching 
is a feature of this patient group. The observed rate of 
peripheral misreaching will provide an estimate of how 
common it is. We will run a further analysis including 
borderline cases and compare the rate of peripheral 
misreaching in each patient group against the appro-
priate chance level of 0.10.
 Group-level analysis
The case–control approach will be complemented by a 
group- level analysis of variance (ANOVA) of reaching 
accuracy, as measured by the PMI, with the between- 
subject factor of group (HC, MCI, AD) and the within- 
subject factor of side (non- dominant, dominant). This 
analysis will test whether the average severity of peripheral 
misreaching in each patient group significantly exceeds 
that observed in HCs.
Exploratory analyses
Any lateralisation that occurs in MCI/AD is likely to be 
limited, therefore, any impairment in peripheral reaching 
may be similarly non- lateralised. An average PMI (across 
both sides) will therefore be calculated to assess periph-
eral reaching ability overall. More detailed analyses will 
be run with a between- subject factor of group and within- 
subject factors of side, eccentricity and viewing condi-
tion. These analyses will be conducted using dependent 
variables of absolute reaching error, directional (signed) 
reaching error, reaction time and movement time. The 
expectation is that peripheral misreaching will manifest 
as a fixation- directed bias, which is exacerbated at higher 
eccentricities significantly more so in patient groups than 
in age- matched controls.
radial reaching task
IRED speed is used to determine onset and offset of the 
reaching movement. Movement onset is defined as the 
first frame in which the IRED’s speed exceeds 50 mm/s 
(and maintains that speed for up to 100 ms). Movement 
offset is defined as the first subsequent frame in which 
IRED speed falls below 50 mm/s. The landing position 
of the movement is defined by the x- coordinate and y- co-
ordinate in the final frame of the movement and will 
be recorded as errors relative to true target locations 
recorded during calibration for each participant.
An initial analysis of PMI for the radial reaching task 
will be performed, restricted to the two most eccentric 
target positions (33.4° and 43.6°). Case–control compar-
isons follow the plan for the lateral reaching task (Anal-
ysis of single case deficits section), to estimate the rates 
of peripheral misreaching, and borderline peripheral 
misreaching, in the two patient groups. Due to different 
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experimental set- ups between the two test sites (UoE, 
UEA), each patient will be referenced to the same- site 
control data for case–control comparisons.
A group level ANOVA of PMI, restricted to the two most 
eccentric target positions, will similarly follow the plan 
for lateral reaching (Group- level analysis section). We 
will include site (UoE, UEA) as an additional covariate. 
More detailed analyses will also follow the plan for lateral 
reaching. Since motion tracking also provides kinematic 
variables on reaching trajectories, we also aim to examine 
the dependent variables peak speed and time to peak 
speed, normalised time after peak speed until reach 
endpoint and number of secondary movements.
Power considerations
The target sample sizes (N=24 per group) are based on 
power considerations related to the main inferential anal-
yses, the case–control comparisons and binomial tests of 
rates of peripheral misreaching deficits for the lateral 
reaching task.
The control sample size of 24 will provide close to 
the maximum power for case–control tests of deficit 
(figure 3A). Note that high power for these compari-
sons is inherently unachievable unless the deficit being 
tested for is very large. We do not know how large any 
misreaching deficits may be in our patient groups, but 
our control sample size will provide close to the maximum 
achievable power to detect them if they exist. Figure 3B 
illustrates more fully the relationship between deficit size 
(D) and power, for the adjusted alpha level (0.025) and 
unadjusted alpha level (0.05) by which we will determine 
peripheral misreaching deficits and borderline cases, 
respectively (Analysis of single case deficits section).
The main hypothesis is that peripheral misreaching 
will be found in a significant proportion of patients with 
AD and MCI. For one- sample binomial test to determine 
whether the observed rate of peripheral misreaching 
exceeds the chance level of 0.05, a sample size of 24 has 
>0.9 power. Provided that the true population proportion 
is at least 0.2 (1 in 5). This is appropriate to our aims, 
since peripheral misreaching would be of limited signifi-
cance in these clinical populations if its prevalence were 
less than 1 in 5.
EthICS And dISSEMInAtIon
This protocol was approved by UK Health Research 
Authority, by the East of England, Cambridge Central 
Research Ethics Committee on 13 June 2019 (REC refer-
ence 19/EE/0170).
All patients will provide informed consent, highlighting 
the voluntary nature of the study and their right to with-
draw. If there is any doubt about the ability of the patient 
to provide informed consent, then this patient will not be 
recruited. There are no direct risks associated with taking 
part.
Careful consideration will be taken to maintain patient’s 
confidentially. After consent is provided, an anonymous 
code will be assigned to each patient. Some patient details, 
such as the Community Health Index (CHI) number, age, 
gender and time of diagnosis, will need to be accessed by 
the research team. These details will be stored alongside 
patient code in a password- protected document.
At the end of the study, a lay summary of results will 
be provided to patients who have expressed a further 
interest. Project results will be made publicly avail-
able on the Open Science Framework (https:// osf. io/ 
bxnqs/) within 3 months after study end date (30 June 
2020). Alongside this, we plan to publish the results of 
this protocol in a peer- reviewed journal and at academic 
conferences.
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